SCHEMBL2453176

SCHEMBL2453176

CN(c1ccc(F)c(N)c1)c1ccc2nc(NC(=O)C3CC3)sc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.55
KDR P35968 3/20 0.55
IKBKB O14920 1/20 0.55
RAF1 P04049 1/20 0.55
ERBB2 P04626 1/20 0.55
CDK1 P06493 1/20 0.55
PDGFRB P09619 1/20 0.55
KIT P10721 1/20 0.55
SRC P12931 1/20 0.55
PDGFRA P16234 1/20 0.55
FGFR3 P22607 1/20 0.55
MAP2K1 Q02750 1/20 0.55
TEK Q02763 1/20 0.55
MAPK14 Q16539 1/20 0.55
AURKB Q96GD4 1/20 0.55
ABL1 P00519 6/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454836 0.84 BRAF (0.61) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2455490 0.84 KDR (0.51) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2455652 0.80 KDR (0.58) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2458469 0.80 KDR (0.57) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL13166316 0.79 NPC1 (0.48) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL12305934 0.79 KDR (0.56) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2458441 0.79 KDR (0.59) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2455663 0.78 KDR (0.58) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2452890 0.78 KDR (0.58) BRAFKDRIKBKBRAF1ERBB2
SCHEMBL2453229 0.78 KDR (0.51) BRAFKDRIKBKBRAF1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
EP-2399921-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-12 EP disclosed
US-8697874-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-15 US disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
EP-2399921-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-12-28 EP disclosed
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-29 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 BRAF 1/4885KDR 983/4885IKBKB 212/4885
US-20110237620-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NR3C2, RAF1 BRAF 1/4885KDR 432/4885IKBKB 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.